Survival and retention of the probiotic properties of Bacillus sp. strains under marine stress starvation conditions and their potential use as a probiotic in Artemia culture

2012 ◽  
Vol 93 (3) ◽  
pp. 1151-1159 ◽  
Author(s):  
Abdelkarim Mahdhi ◽  
Maria Ángeles Esteban ◽  
Zeineb Hmila ◽  
Karima Bekir ◽  
Fathi Kamoun ◽  
...  
Keyword(s):  
Probiotic Properties ◽  
Bacillus Sp ◽  
Potential Use ◽  
Starvation Conditions

scholarly journals Optimisation De La Production De L’ α-Amylase Par Les Microorganismes Isolés Des Ferments Traditionnels De Manioc Provenant De Trois Zones De Production De L’attiéké En Côte d’Ivoire

2016 ◽  
Vol 12 (9) ◽  
pp. 259
Author(s):  
Bouatenin Koffi Maïzan Jean-Paul ◽  
Djéni N’dédé Théodore ◽  
Kakou Abodjo Célah ◽  
Menan Eby Hervé ◽  
Dje Koffi Marcellin
Keyword(s):  
Lactobacillus Casei ◽  
Research Work ◽  
Starter Cultures ◽  
Bacillus Sp ◽  
Amylase Production ◽  
Optimal Duration ◽  
Microbial Strains ◽  
Kinetics Of ◽  
Potential Use

This research work aimed at studying production kinetic of α-amylase by microbial strains isolated from three traditional cassava ferments; with a view of their potential use as starter cultures. The study was carried out on 42 amylolytic strains comprising 15 lactic acid bacteria species, 9 yeast, 9 Bacillus sp. And 9 moulds. Amyloytic activities were assessed in vitro in a broth. Independently of strains and their origin, results showed three α-amylase regulation kinetics. From the 3 species which constitutively secrete α-amylase, only Candida tropicalis LVX8 excretes a large amount of α-amylase (171.33 ± 3 EU/mL) in 24 hours. Among strains, which α-amylase excretion is regulated by a repression, the optimal duration for each one of them varied from 4 to 24 hours. Thus, Lactobacillus casei LABZ4 secretes within 4 hours of culture, 47.3 ± 1.41 EU/mL, whereas yeast (LVX1, LVZ19, LVY16 and LVZ1), moulds (MZ2, MZ1 and MY2) and Bacilli (BX5, BY4 and BZ15) strains excreted each during 12 to 20 hours α-amylase amounts ranging from 60 ± 3.7 and 106 ± 1.3 EU/mL. For strains with amylase production modulated by inactivation, maximal amounts of enzymes were very low and reached after only 4 hours. However, for yeasts LVX14, LVY3 and LVZ18, inactivation was observed from 16 hours, with activities higher than 100 EU/mL. Considering the diversity of production kinetics of α-amylase, the use of these isolates for a controlled fermentation of cassava dough would be optimal in co-culture.

The growth of mica polytypes as studied by conventional and high-resolution TEM

1983 ◽  
Vol 41 ◽  
pp. 174-177
Author(s):  
A. Baronnet ◽  
M. Amouric
Keyword(s):  
Water Pressure ◽  
Point Of View ◽  
Temperature Fields ◽  
Natural Occurrence ◽  
Growth Mechanisms ◽  
Long Period ◽  
High Resolution Tem ◽  
Layer Stacking ◽  
Experimental Works ◽  
Potential Use

The origin of mica polytypes has long been a challenging problem for crystal- lographers, mineralogists and petrologists. From the petrological point of view, interest in this field arose from the potential use of layer stacking data to furnish further informations about equilibrium and/or kinetic conditions prevailing during the crystallization of the widespread mica-bearing rocks. From the compilation of previous experimental works dealing with the occurrence domains of the various mica "polymorphs" (1Mr, 1M, 2M1, 2M2 and 3T) within water-pressure vs temperature fields, it became clear that most of these modifications should be considered as metastable for a fixed mica species. Furthermore, the natural occurrence of long-period (or complex) polytypes could not be accounted for by phase considerations. This highlighted the need of a more detailed kinetic approach of the problem and, in particular, of the role growth mechanisms of basal faces could play in this crystallographic phenomenon.

An atomic-resolution microscope study of Al contracts on GaAs

1986 ◽  
Vol 44 ◽  
pp. 726-727
Author(s):  
Z. Liliental-Weber ◽  
C. Nelson ◽  
R. Ludeke ◽  
R. Gronsky ◽  
J. Washburn
Keyword(s):  
High Speed ◽  
Schottky Contacts ◽  
Detailed Knowledge ◽  
The Past ◽  
Semiconductor Interfaces ◽  
Deposited Metal ◽  
Microwave Applications ◽  
Free Interfaces ◽  
Potential Use

The properties of metal/semiconductor interfaces have received considerable attention over the past few years, and the Al/GaAs system is of special interest because of its potential use in high-speed logic integrated optics, and microwave applications. For such materials a detailed knowledge of the geometric and electronic structure of the interface is fundamental to an understanding of the electrical properties of the contact. It is well known that the properties of Schottky contacts are established within a few atomic layers of the deposited metal. Therefore surface contamination can play a significant role. A method for fabricating contamination-free interfaces is absolutely necessary for reproducible properties, and molecularbeam epitaxy (MBE) offers such advantages for in-situ metal deposition under UHV conditions

The potential use of short chain peptides in parenteral nutrition

1985 ◽  
Vol 4 ◽  
pp. 116-123 ◽  
Author(s):  
P STEHLE ◽  
S ALBERS ◽  
I AMBERGER ◽  
P PFAENDER ◽  
P FURST
Keyword(s):  
Parenteral Nutrition ◽  
Short Chain ◽  
Potential Use

Instant 99mTc Compounds

1971 ◽  
Vol 10 (03) ◽  
pp. 245-251 ◽  
Author(s):  
P. Richards ◽  
W. C. Eckelman
Keyword(s):  
Physical Properties ◽  
High Purity ◽  
Analytical Techniques ◽  
Full Potential ◽  
Labeled Compounds ◽  
Ph Adjustment ◽  
One Step ◽  
Stannous Ion ◽  
99Mtc Radiopharmaceuticals ◽  
Potential Use

SummaryThe full potential use of technetium has not been achieved despite its ideal physical properties, dosimetry and availability because of the complex preparations required for 99mTc radiopharmaceuticals. One of the goals of our work is to develop techniques for the preparation of high-purity 99mTc compounds which can be easily prepared, ideally by adding pertechnetate to a prepared solution.The use of stannous ion as reducing agent for technetium makes it possible to obtain such one-step, high-purity products. All non-radioactive components can be premixed in a single vial before addition of the radioactive pertechnetate. No final pH adjustment, further chemical manipulation or purification is required.Procedures for two instantly labeled compounds have been developed to date: 99mTc DTPA and 99mTc HSA. The 99mTc DTPA is prepared by adding pertechnetate to a previously prepared solution of stannous ion and CaNa3 DTPA which has been stored at pH 4. The 99mTc HSA is prepared by adding pertechnetate to a solution of stannous ion and HSA. The parametric variations and analytical techniques involved in formulating these procedures are described. It appears that development of kits for other biologically interesting compounds may be possible using similar procedures.

Treatment and secondary prevention of venous thromboembolism in cancer patients

2012 ◽  
Vol 03 (03) ◽  
pp. 121-125
Author(s):  
I. Pabinger ◽  
C. Ay
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
New Oral Anticoagulants ◽  
Phase Iii ◽  
Patients With Cancer ◽  
Potential Use

SummaryCancer is a major and independent risk factor of venous thromboembolism (VTE). In clinical practice, a high number of VTE events occurs in patients with cancer, and treatment of cancerassociated VTE differs in several aspects from treatment of VTE in the general population. However, treatment in cancer patients remains a major challenge, as the risk of recurrence of VTE as well as the risk of major bleeding during anticoagulation is substantially higher in patients with cancer than in those without cancer. In several clinical trials, different anticoagulants and regimens have been investigated for treatment of acute VTE and secondary prophylaxis in cancer patients to prevent recurrence. Based on the results of these trials, anticoagulant therapy with low-molecular-weight heparins (LMWH) has become the treatment of choice in cancer patients with acute VTE in the initial period and for extended and long-term anticoagulation for 3-6 months. New oral anticoagulants directly inhibiting thrombin or factor Xa, have been developed in the past decade and studied in large phase III clinical trials. Results from currently completed trials are promising and indicate their potential use for treatment of VTE. However, the role of the new oral thrombin and factor Xa inhibitors for VTE treatment in cancer patients still has to be clarified in further studies specifically focusing on cancer-associated VTE. This brief review will summarize the current strategies of initial and long-term VTE treatment in patients with cancer and discuss the potential use of the new oral anticoagulants.

Sign in / Sign up

Export Citation Format

Share Document